Acamprosate: potential medication for treating alcoholism

laces and things associated with alcohol) and reduce alcohol consumption, leading to less relapse drinking and more abstinent days. Although it is well tolerated and does not produce many adverse effects, naltrexone does not work for everyone, leading some scientists to think there are genetic differences behind the treatment response.

For this study, adult participants (7 males, 3 females) were recruited through local advertising. All of the participants were classified as heavy drinkers, having reported alcohol consumption a minimum of eight days per month; with five or more drinks per occasion at least three times a month for the men, and four or more drinks per occasion at least three times a month for the women. During the six-week study, subjects received three different doses of oral acamprosate (0, 2 and 4 g.) for 11 days on each dose. Physiological, subjective and psychomotor measures were collected daily during each dosing cycle. During each of the acamprosate dose conditions, subjects also received three different doses of alcohol (0, 0.5 and 1.0 g/kg) during three separate laboratory sessions. Researchers collected the subjective, physiological and psychomotor effects of the alcohol as well as breath-alcohol levels at baseline and at 30-minute intervals for three hours following administration.

Results indicate that acamprosate does not appear to alter alcohol's pharmacokinetics (the way it moves through the body), acute physiological or psychomotor alcohol effects, or most subjective alcohol effects.

"While the results of this study are rather clear and straightforward, namely, that acamprosate has minimal effects on the alcohol experience, the findings should be interpreted cautiously because only a few subjects were studied and those subjects were not alcoholics," said Anton. "Since people vary in medication response, generalizing from a study of only a few people is difficult. Also, we know tha


Page: 1 2 3 4

Related biology news :

1. Award winning researchers reveal potential new role for Glivec
2. Evidence builds for potential new cancer drug target
3. Scientists discover potential new way to control drug-resistant bacteria
4. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
5. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
6. Managing occupational exposures to potential bioterrorist agents
7. Location of potential familial lung cancer gene discovered
8. Common chemicals morphing into potential toxins in Arctic
9. Yale researchers discover new potential asthma therapeutic targets related to parasites and insects
10. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
11. New screening method turns up potential compound for treating anthrax

Post Your Comments:
TAG: Acamprosate potential medication for treating alcoholism

(Date:3/3/2015)... LAKE FOREST, Calif. , March 3, ... ("Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, today announced the ... Hutchinson Cancer Research Centers, ("Fred Hutch") ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
(Date:3/6/2015)... Strategic marketing and branding agency, Red ... Able&Co. , The agency was founded in 2008 by ... inception, continuing to expand its business each year. “We ... a core focus on branding and marketing strategy. As ... and visual identity to reflect who we have become ...
(Date:3/6/2015)... March 6, 2015   InspireMD, Inc. (NYSE MKT: ... systems, announced today that it will release its full financial ... 2014 on Thursday, March 12 th after market close, ... review its financial results and business outlook. Participants ... or (412) 542-4135 (International) and request the InspireMD call. A ...
(Date:3/6/2015)... According to a new market research report ... Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) by Application ... Global Forecast to 2019", published by MarketsandMarkets, the Soft ... in 2019 from $10.3 Billion in 2014, at a ... Browse 70 market data tables and 32 ...
(Date:3/6/2015)... St. Paul, Minn. (PRWEB) March 06, 2015 ... cutting edge Scientific Symposia sessions for the grain ... call for abstracts. , 2015 marks the ... holding its Centennial Meeting in Minneapolis, Minnesota, U.S.A. ... forward-thinking presentations from international researchers who are looking ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2
Cached News: